Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|September 13, 2000

Capsule camera clinical trials begin this month

The developers of the innovative “gut cam” will begin clinical testing this month, and have picked ShellCase of Jerusalem to design a package for the miniature technology.An announcement in June (SCAN 6/7/00) that researchers have

The developers of the innovative “gut cam” will begin clinical testing this month, and have picked ShellCase of Jerusalem to design a package for the miniature technology.

An announcement in June (SCAN 6/7/00) that researchers have devised a miniature camera-in-a-capsule, dubbed the “M2A,” that can traverse the entire digestive system made big news, but the revolutionary imaging technology is several years away from the market.

The ultra-small image sensor, which was developed by Pasadena, CA-based Photobit and is being produced by Given Imaging of Yoqneam, Israel, is 1 inch long and one-third of an inch in diameter, and will be contained in an ingestible capsule that is swallowed like a pill.

Patients will wear an antenna array and a wireless recorder on a waist belt, which picks up signals transmitted by the capsule during its six-hour trip.

Given has designed a computer workstation that processes the data and produces a 20-minute video clip of the camera’s images.

Given officials said the device had passed preliminary FDA tests on animals and volunteers. The company applied for FDA approval in May. They expect the pill will cost patients about $300, while the cost to hospitals, including receptors and computer station, will be $30,000.

The ShellOP packaging technology is used for image sensors, light detection devices, and other optical applications. Given chose it because is the only package that is small enough, has good optical characteristics, and is cost-effective and simple to assemble.

When it is ready for sale, the disposable capsule camera will be marketed by Given, a developer of platform technology for GI diagnostics and therapy.

Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Current Perspectives on Integrating AI into Radiology
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.